P&G Hygiene & Healthcare Limited's (P&G) third quarter performance reflects the difficult market conditions the FMCG sector has been facing. The company declared a 9% topline growth in the December quarter, but finished the March quarter with a significant 11% decline in topline growth.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Earnings per share*
Current P/e ratio
The company finished the quarter with a 42% decline in profits to Rs 121 m. However, the company's release says that P&G had earned an extraordinary income of Rs 100.5 m in March quarter last year, and therefore, has actually registered a 12% growth in net profit YoY. This extraordinary income must have arisen due to sales adjustments in the March quarter last year.
However, in March quarter last year the company did not elaborate on how these extraordinary gains came about. The management of P&G seems to be giving this aspect prominence now. How this extraordinary item affected the March quarter numbers in the previous year is therefore not clear to us, so we are keeping our last year's March quarter figures intact.
Raw material cost
Apart from the decline in topline, another worrying aspect is a huge 10% drop in operating margins to 22%. This is another sign of the difficult market conditions P&G is facing. On a nine month basis, the performance is somewhat better. The company has logged in a marginal 1% decline in sales and a 7% drop in net profits. If we take out the extraordinary income P&G earned in FY02 (till date) then the company actually saw profits decline by 17% during the nine month period. In 9mFY02 too, the pressure on margins is evident.
Commenting on the performance Mr. Bharat Patel, Chairman, P&G said "Our third quarter sales are down because of continuing slowdown in economy resulting in decline in most established packaged consumer goods category. We have strong plans for the remaining part of the fiscal and next year so that sales decline turns into significant sales increase"
At the current price of Rs 465 the stock trades at a P/E of 11x 9mFY02 annualised earnings. Given the company's focus on operational efficiencies, the valuation is on the lower side. This is probably because of the company's two product dependence as well as concerns regarding the parent's 100% subsidiaries. Also, the company's 3QFY02 performance is sending warning signals about the pressure on the company's core business.
Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407